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ABSTRACT
Objective: Neuropathological descriptions of the brain in
Friedreich’s ataxia (FRDA) were obtained before avail-
ability of the current molecular genetic tests for this
disease. Voxel-based morphometry (VBM) enables an
unbiased whole-brain quantitative analysis of differences
in gray matter (GM) and white matter (WM) volume.
Methods: Using VBM, we assessed the brain structural
damage in 22 patients with genetically confirmed FRDA
and 25 healthy controls. The results were correlated with
the disease duration and the severity of the patients’
clinical deficits—evaluated using the International
Cerebellar Ataxia Rating Scale and Inherited Ataxia Clinical
Rating Scale.
Results: In patients with FRDA, VBM showed a
symmetrical volume loss in dorsal medulla, infero-medial
portions of the cerebellar hemispheres, the rostral vermis
and in the dentate region. No volume loss in cerebral
hemispheres was observed. The atrophy of the cerebel-
lum and medulla correlated with the severity of the clinical
deficit and disease duration.
Conclusions: In patients with FRDA, significant GM and
WM loss was observed only in the cerebellum and dorsal
medulla. These structural changes correlate with the
severity of the clinical deficit and disease duration.
Friedreich’s ataxia (FRDA) is the most common
inherited ataxia and, in most cases, is due to a GAA
repeat expansion in a gene on chromosome 9q13,
which codes for a mithocondrial protein named
frataxin.1
Neurological features include progressive ataxia
and impaired vibration or position sense, areflexia
of the lower extremities, pyramidal-tract dysfunc-
tion, distal muscular atrophy and dysarthria,
which are accompanied by skeletal deformities,
cardiomyopathy and diabetes mellitus.1 Atypical
clinical variants are frequent, which makes mole-
cular diagnostic testing fundamental for the
diagnosis of FRDA.
Neuropathological descriptions of the brain in
FRDA were obtained before the availability of the
current molecular genetic tests.2 3 Magnetic reso-
nance imaging (MRI) demonstrates in vivo atrophy
of the main CNS structures that are involved in
FRDA—namely, the spinal cord and the medulla—
whereas atrophy of the cerebellum and of the
cerebral hemispheres were occasionally reported.4–7
Voxel-based morphometry (VBM) is an unbiased
whole-brain method that assesses regional differ-
ences between brain gray matter (GM) and white
matter (WM) volume in T1-weighted images,8 and
has been widely applied to the investigation of
atrophy in patients with degenerative CNS dis-
eases. We hypothesised that VBM could help to
establish, in vivo, the structural damage of the brain
in patients with genetically proven FRDA and
correlated the findings with clinical features.
PATIENTS AND METHODS
Between March 2005 and March 2007, 22 (12
women and 10 men; mean age 33¡10 years, range
13–54 years) with genetically proven FRDA gave
their informed consent to participate in this
prospective study, which was approved by the
Local Ethical Committee.
A molecular diagnostic method was previously
reported9 and the cut-off number of expansion of
triplet repeats qualifying for diagnosis was 100
GAA on both alleles for FRDA. In the 22 patients,
the mean number of triplets in the shorter alleles
was 646 ¡22 and in the longer alleles 895 ¡212.
On the day of the MRI examination, the same
neurologist (blind to the results of MRI) defined
the patient’s disease duration and computed her or
his scores on the International Cooperative Ataxia
Rating Scale (ICARS)10 and on the Inherited Ataxia
Clinical Rating Scale (IACRS).11 The ICARS is a 0–
100 semi-quantitative scale, with 100 correspond-
ing to maximal clinical deficit; it evaluates 19
different features of the cerebellar syndrome. The
IACRS is a 0–46 semi-quantitative scale, with 46
corresponding to maximal clinical deficit; it eval-
uates signs and symptoms related to ataxia,
pyramidal-tract dysfunction, and impaired vibra-
tion or position sense. The mean disease duration
in the patients was 14.5 ¡9.2 (range 5–39) years,
their mean ICARS score was 54 ¡22 (range 17–96)
and their mean IACRS score was 25¡7 (range 9–36).
Twenty-five healthy volunteers without perso-
nal or familial history of neurological disease (10
women and 15 men; mean age 37¡11 years, range
26–66 years) served as controls.
MRI examination
Patients and controls underwent MRI examination
in a single centre on a 1.5T system (Philips Intera;
Best, The Netherlands) with 33 mT/m maximum
gradient strength and SENSE coil technology. After
scout, axial 3D T1-weighted turbo gradient echo
(repetition time = 25 ms, echo time = 4.6 ms, flip
angle = 30u, field of view = 256 mm, matrix
size = 256 6 256, 160 contiguous slices, slice
thickness = 1 mm) images were obtained for
VBM in all FRDA patients and controls.
Data processing
Image data processing was performed on a PC
running MATLAB 7 (The Mathworks, Inc., Natik,
MA, USA) and the statistical parametric mapping
2 (SPM2) software (Wellcome Department of
Cognitive Neurology, London, UK).
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The methodology of VBM closely followed that previously
reported8 and included seven steps: reorientation according to
the antero-posterior commissure line; template creation to
improve brain segmentation; normalisation; segmentation into
three classes of tissue (GM, WM and CSF); modulation;
smoothing with a 8 mm full-width half-maximum Gaussian
kernel; voxelwise between-groups statistical analysis.
Statistical methods
VBM
Statistical analysis of the MRI data was based on the general
linear model and the theory of Gaussian random fields. A
voxelwise comparison of spatially normalised T1-weighted
images was made using SPM2. Group comparisons were
performed by means of analysis of covariance (ANCOVA)
using the total volume of each segmented image (GM volume
for GM analysis, WM volume for WM analysis) as confounding
covariate. Age and gender were included as covariates of no
interest to exclude the possible effects of these variables on
regional GM or WM volumes.8
Voxel-level analysis with a significance threshold set at p-
value ,0.05 corrected for multiple comparisons across the
whole brain (family-wise error correction) were applied to the
resulting t-statistic maps of GM and WM.
To correlate the extent of GM or WM volume loss with
severity of the clinical deficit, disease duration and GAA repeat
number of the longer allele, the significant areas at group
analysis were saved and applied as regions of interest (ROI) on
the maps of local average volume of each patient. Extracted
local average volumes for each region of decreased GM or WM
were finally correlated to ICARS and IACRS scores, disease
duration and GAA repeat number of the longer allele by means
of the Spearman rank correlation test (p,0.05).
The Schmahmann et al. MRI atlas of the human cerebellum12
was used as an anatomical reference to assess the exact
localisation of significantly atrophic GM.
RESULTS
Voxel-based morphometry showed symmetrical loss of the GM in
the rostral vermis (lobules I–III) (cluster extent 1684; coordinates:
24, 241, 224; Z = 6.25) and in the dorsal medulla and infero-
medial portions of the cerebellar hemispheres (lobules IX) (cluster
extent 1458; coordinates 1,248,258; Z = 6.24) and of the WM in
the dentate region (right cluster extent 2602; coordinates 6, 256,
230; Z = 7.06; left cluster extent 964; coordinates 28, 254, 231;
Z = 8.0) in FRDA patients compared with healthy controls (fig 1).
Figure 1 Maps of the t-value (voxel
analysis at p,0.05 corrected for multiple
comparisons) represented as glass brain
(A, B) and superimposed on T1-weighted
images (C, D), showing nearly
symmetrical loss of the gray matter (GM)
in the rostral vermis (lobules I–III), the
dorsal medulla and infero-medial portions
of the cerebellar hemispheres (lobules IX)
(A and C) and of the white matter (WM)
in the dentate region (B and D) in patients
with Friedreich’s ataxia (FRDA) compared
with healthy controls. No supratentorial
GM or WM volume loss is present.
Table 1 Spearman’s rank correlation coefficients between local
average volume, clinical scores and GAA repeat number of the longer
allele in 22 patients with inherited ataxias
FRDA
WMGM
ICARS 20.71** 20.66**
IACRS 20.46* 20.49*
Disease duration 20.53* 20.49*
GAA repeat number of the
longer allele
20.19 20.19
*p,0.05; **p,0.001
FRDA, Friedreich’s ataxia; GM, gray matter; IACRS, Inherited Ataxia Clinical Rating
Scale; ICARS, International Cooperative Ataxia Rating Scale; WM, white matter.
Short report
J Neurol Neurosurg Psychiatry 2008;79:82–85. doi:10.1136/jnnp.2007.124297 83
 on 26 March 2008 jnnp.bmj.comDownloaded from 
No significant cluster of GM or WM volume reduction was
observed in the cerebral hemispheres.
The volume loss of the GM and WM correlated with all the
clinical variables but not with the GAA repeat number of the
longer allele (table 1, fig. 2).
DISCUSSION
The combination of molecular genetic diagnosis with VBM
offers the possibility of performing a structural assessment, in
vivo, of a given disease condition—without the limitations that
are inherent to neuropathological examination. Such limitations
include the usually small number of cases, technical problems
(fixation artefacts, etc.), sample (a whole brain neuropatholo-
gical examination is rarely performed) bias and the coexistence
of agonal changes.
Voxel-based morphometry was applied to the investigation of
patients with spinocerebellar ataxia type 2,13 type 3, type 614 and
type 17,15 but no VBM study evaluated patients with FRDA.
The neuropathological hallmark of FRDA is neuronal loss and
shrinkage in the spinal ganglion cells and in the Clarke column
of the spinal cord, with degeneration of the gracilis and
cuneatus tracts in the posterior columns and of the spinocer-
ebellar tracts in the lateral columns of the spinal cord.2 3
Secondary neuronal loss in the brainstem predominantly
involves the accessory cuneate and gracilis nuclei in the dorsal
medulla. The most striking feature in the cerebellum is loss of
neurons in the dentate nuclei, whereas the cerebellar cortex is
spared.3 The cerebellar WM is diffusely gliotic and there is loss
of the myelinated fibres in the hilum of the dentate nuclei.2 3
Cell loss and astrocytosis occurs in the vestibular and cochlear
nuclei and in the superior olives, whereas the inferior olives are
spared. Most cases show degenerative changes in the corticosp-
inal tracts at the level of the medulla and below, whereas
pathological changes in the supratentorial compartment are
usually restricted to optic nerve and tract damage.3
Magnetic resonance imaging studies in patients with FRDA,
using visual assessment or measurement of the region of interest
of CNS structures in the posterior cranial fossa and cervical
spine, pointed out atrophy of the cervical spinal cord and
medulla.4 Atrophy of the superior vermian and paravermian
areas (culmen and declive lobules) of the cerebellum and of the
cerebral hemispheres were visually noted in some studies.5–7
In the present VBM study of patients with genetically proven
FRDA, we demonstrated GM volume loss in the dorsal medulla
and the rostral cerebellar vermis, inferomedial cerebellar hemi-
spheres and of WM in the region of the dentate, but no atrophy
of the cerebral hemispheres. The atrophy of the dorsal medulla,
where the relais between the gracilis and cuneatus tracts of the
spinal cord and the corresponding nuclei is located, and the
atrophy of the cerebellar WM in the dentate region, match the
neuropathological descriptions. In addition, the distribution of
GM atrophy in the cerebellum is partially in line with that
noted in a previous study.5 In our opinion, the failure in our
study to demonstrate atrophy of the dentate, which is a very
small GM structure, and other small GM and WM structures of
the brainstem, exemplifies the difficulties of using VBM to
evaluate the CNS structures contained in the posterior cranial
fossa (RDN, unpublished observation, 2007). These difficulties
presumably arise from problems with spatial normalisation due
to high variability between subjects of small structures and
regional differences in the quality of GM and WM segmenta-
tion. In particular, the latter could be influenced by partial
volume between CSF and GM secondary to atrophy or signal
changes related to pathology, decreasing the GM/WM contrast.
Diffusion tensor imaging represents an alternative tool for
evaluation of the WM of the brainstem and cerebellum, but this
was not investigated in this study.
A general expectation for imaging data in inherited ataxias
and other neurodegenerative diseases of the CNS is that they
could provide useful markers of severity of neurodegeneration.15
In our study, atrophy of the dorsal medulla, rostral vermis,
inferomedial cerebellar hemispheres and of the peridentate WM
correlated with clinical severity and disease duration. As in
previous MRI studies of inherited ataxias, including FRDA,16
SCA117 and SCA2,13 we found no correlation between the
severity of atrophy and number of triplet expansions.
We recognise that our study was limited by the fact that the
gender of the patients and controls was unbalanced, and that
their age was similar but not matched.
Regarding the distribution of neuropathological changes, it is
anticipated that atrophy of the spinal cord is likely to be equally or
even more strictly correlated with disease severity and duration
than brain atrophy in patients with FRDA. However, correlation
analyses between clinical severity and the size (and, possibly,
structure) of the spinal cord in patients with FRDA are lacking.
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